Michael Hudecek

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
    Michael Hudecek
    Clinical Research Division, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 116:4532-41. 2010
  2. pmc Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells
    Michael Hudecek
    Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Cancer Res 19:3153-64. 2013
  3. pmc Adoptive T-cell therapy for B-cell malignancies
    Michael Hudecek
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Expert Rev Hematol 2:517-32. 2009
  4. pmc Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells
    Marie Bleakley
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 115:4923-33. 2010
  5. pmc Engineered T cells for anti-cancer therapy
    Cameron J Turtle
    Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
    Curr Opin Immunol 24:633-9. 2012
  6. pmc Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia
    Tetsuya Nishida
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 15:4759-68. 2009
  7. pmc Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen
    Sebastian Ochsenreither
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 119:5492-501. 2012

Detail Information

Publications7

  1. pmc The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
    Michael Hudecek
    Clinical Research Division, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 116:4532-41. 2010
    ..T-cell therapies targeting ROR1 may be effective in B-CLL and other ROR1-positive tumors. However, the expression of ROR1 on some normal tissues suggests the potential for toxi-city to subsets of normal cells...
  2. pmc Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells
    Michael Hudecek
    Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Cancer Res 19:3153-64. 2013
    ....
  3. pmc Adoptive T-cell therapy for B-cell malignancies
    Michael Hudecek
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Expert Rev Hematol 2:517-32. 2009
    ..These advances provide the tools to translate adoptive T-cell transfer into reliable clinical therapies...
  4. pmc Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells
    Marie Bleakley
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 115:4923-33. 2010
    ....
  5. pmc Engineered T cells for anti-cancer therapy
    Cameron J Turtle
    Program in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
    Curr Opin Immunol 24:633-9. 2012
    ....
  6. pmc Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia
    Tetsuya Nishida
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Clin Cancer Res 15:4759-68. 2009
    ..We evaluated the development of CTLs specific for CLL after NM-HSCT to determine if their presence correlated with antitumor efficacy...
  7. pmc Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen
    Sebastian Ochsenreither
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 119:5492-501. 2012
    ..The pro-oncogenic activity, high expression levels, and multitude of immunogenic epitopes make it a viable target for pursuing T cell-based therapy approaches...